Clinical Trial 24170

• Overview

  Study Title:

  A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)

• Treatments

  Therapies:

  Chemotherapy (NOS); RAS MULTI(ON) inhibitor

  Medications:

  Daraxonrasib (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); RMC-6236 (Daraxonrasib); RMC-9805 (Zoldonrasib); Zoldonrasib (); gemcitabine ()

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.